The risk of increasing tumor malignancy after PET diagnosis
Agnieszka Korga-Plewko(Medical University of Lublin), Sławomir Mańdziuk(Medical University of Lublin), Beata Chrapko(Medical University of Lublin), Magdalena Iwan(Medical University of Lublin), Jarosław Dudka(Medical University of Lublin), Ewa Poleszak(Medical University of Lublin), Marta Ostrowska-Leśko(Medical University of Lublin), Jarosław Szponar(Medical University of Lublin), Luiza Grzycka‐Kowalczyk(Medical University of Lublin), Brygida Ślaska(University of Life Sciences in Lublin), Andrzej Wróbel(Medical University of Lublin), Monika Cendrowska‐Pinkosz(Medical University of Lublin)
Cited by 0
Related Papers
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
|Annals of Oncology|2020|164
Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells
|BMC Pharmacology and Toxicology|2019|61
Inhibition of glycolysis disrupts cellular antioxidant defense and sensitizes HepG2 cells to doxorubicin treatment
|FEBS Open Bio|2019|50
The effect of a number of H9C2 rat cardiomyocytes passage on repeatability of cytotoxicity study results
|Cytotechnology|2016|48
The Role of Molecular and Inflammatory Indicators in the Assessment of Cognitive Dysfunction in a Mouse Model of Diabetes
|International Journal of Molecular Sciences|2021|43